ARS Pharmaceuticals News

Buy Rating on ARS Pharmaceuticals Amid Strong Neffy Approval Prospects and Indication Expansion

TipRanksMar 24 21:25 ET

Ars Pharmaceuticals' Merger May Limit Use of Net Operating Losses, Impacting Future Financials

TipRanksMar 23 02:01 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaMar 11 08:44 ET

Neffy's Market Potential and ARS Pharmaceuticals' Buy Rating Reinforced by Clinical Success

TipRanksMar 11 06:45 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaMar 5 07:10 ET

Leerink Partners Upgrades ARS Pharmaceuticals to Outperform, Raises Price Target to $18

BenzingaMar 5 07:11 ET

Hold Rating Maintained for ARS Pharmaceuticals Amid FDA Approval Process and Commercialization Concerns

TipRanksFeb 22 00:16 ET

Buy Rating Affirmed: ARS Pharmaceuticals' Neffy Shows Promise in Clinical Trials With Strong Market Potential

TipRanksFeb 6 11:05 ET

Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Wave Life Sciences (WVE) and AC Immune SA (ACIU)

TipRanksNov 14, 2023 03:20 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaNov 13, 2023 08:59 ET

Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Healthequity (HQY)

TipRanksNov 13, 2023 07:11 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaSep 21, 2023 09:28 ET

Wedbush Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

TipRanksSep 21, 2023 06:55 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaSep 20, 2023 06:08 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), National Health Investors (NHI) and ARS Pharmaceuticals (SPRY)

TipRanksSep 20, 2023 04:50 ET

Wedbush Remains a Buy on ARS Pharmaceuticals (SPRY)

TipRanksAug 14, 2023 08:36 ET

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $15 Price Target

BenzingaAug 14, 2023 08:17 ET

ARS Pharmaceuticals Analyst Ratings

BenzingaAug 14, 2023 08:17 ET

SVB Securities Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

TipRanksJun 22, 2023 05:55 ET

Wedbush Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $15

BenzingaJun 21, 2023 08:46 ET